Molecular pathways: MERTK signaling in cancer.

@article{Cummings2013MolecularPM,
  title={Molecular pathways: MERTK signaling in cancer.},
  author={Christopher T. Cummings and Deborah Deryckere and H Shelton Earp and Douglas K. Graham},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 19},
  pages={5275-80}
}
MERTK is a receptor tyrosine kinase of the TAM (Tyro3, Axl, MERTK) family, with a defined spectrum of normal expression. However, MERTK is overexpressed or ectopically expressed in a wide variety of cancers, including leukemia, non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, breast cancer, colon cancer, gastric cancer, pituitary adenomas, and rhabdomyosarcomas, potentially resulting in the activation of several canonical oncogenic signaling pathways. These include the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 64 references

Inhibition ofMer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity

  • KeatingAK, KimGK, JonesAE, DonsonAM, WareK, MulcahyJM
  • Mol Cancer Ther 2010;9:1298–307
  • 2010
Highly Influential
10 Excerpts

Galectin-3 is a newMerTKspecific eat-me signal

  • NB Caberoy, G Alvarado, JL Bigcas, W. Li
  • J Cell Physiol 2012;227:401–7
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…